Overview

International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel

Status:
Unknown status

Trial end date:
2018-02-01

Target enrollment:

Participant gender:

Summary

Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease. The aim of this phase II study is compare two well known and largely used chemotherapy regimens - Cisplatin plus 5-fluorouracil vs Carboplatin plus Paclitaxel. The result of this study will set a standard of care for this disease and provide useful information for future Phase III trials.

Phase:

Phase 2

Details

Lead Sponsor:

Royal Marsden NHS Foundation Trust

Collaborators:

Australasian Gastro-Intestinal Trials Group
Cancer Research UK
ECOG-ACRIN Cancer Research Group
European Organisation for Research and Treatment of Cancer - EORTC
International Rare Cancers Initiative (IRCI ) This study is indorsed by IRCI

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Fluorouracil
Paclitaxel